Is Boron Bone Health Randomized Trial safe?

The current Migaku evidence database contains 2 reusable source documents for Boron Bone Health Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - 1 2 1 2 Osteoporosis, the primary risk factor for fragility fractures, is highly prevalent and projected to increase as populations age globally [,]. [Treister-Goltzman Yulia (2026); evidence level 1] - Fragility fractures, particularly of the hip, spine, and wrist, are associated with substantial morbidity, loss of independence, increased mortality, and considerable healthcare costs, making osteoporosis a significant public health concern [,]. [Treister-Goltzman Yulia (2026); evidence level 1] - Evidence from multiple in vitro biochemical and cell culture studies [,,], as well as preclinical investigations using ovariectomized and estrogen-deficient rodent models [,,,,,], consistently supports a favorable effect of prunes or prune-derived components on bone metabolism. [Treister-Goltzman Yulia (2026); evidence level 1] - However, due to the limited number of human studies investigating the effects of vitamin D supplementation on implant outcomes, the current evidence remains weak and preliminary [,]. [Sodnom-Ish Buyanbileg (2026); evidence level 4] - 10 Despite the recent growing interest and research insights, there is limited evidence on how the deficiency or supplementation of other micronutrients (e.g., boron, selenium, copper, or iron) influences osseointegration or the long-term implant survival and success. [Sodnom-Ish Buyanbileg (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.